In a nutshell This study investigated whether brentuximab vedotin (Adcedris; BC) + AVD (doxorubicin, vinblastine, and dacarbazine) chemotherapy combination resulted in a reduction or elimination of consolidative radiotherapy in early-stage unfavorable-risk Hodgkin lymphoma (HL). The data showed that the BV+AVD combination with and without...
Read MoreType(s) of chemotherapy-ABVD Posts on Medivizor
Is PET-guided exclusion of radiotherapy an appropriate treatment regimen for unfavorable early-stage Hodgkin lymphoma?
In a nutshell The authors investigated the impact of removing radiotherapy (RT) from treatment regimens in patients with early-stage unfavorable Hodgkin lymphoma (HL). This study concluded that this treatment regimen is just as effective as the standard of care. Some background Chemotherapy and consolidation RT is the standard of care for...
Read MoreEarly-stage Hodgkin lymphoma and radiation therapy doses
In a nutshell The purpose of this study was to assess the dose of radiation delivered to organs at risk with modern radiotherapy (RT) in patients with early-stage Hodgkin lymphoma (HL). The authors found that 2 cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and 20Gy of RT for early-stage HL was highly effective...
Read MoreWhat are the effects of lenalidomide, doxorubicin, vinblastine and dacarbazine in Hodgkin lymphoma?
In a nutshell This study investigated the effects of adding lenalidomide (Revlimid) to doxorubicin (Adriamycin), vinblastine (Velban), and dacarbazine (DTIC-Dome) treatment for older patients with Hodgkin lymphoma (HL). The main finding was that this combination is effective but severe side-effects may be experienced. Some background HL is a cancer...
Read MoreSearching for patients with early stage Hodgkin lymphoma to try brentuximab vedotin and nivolumab
In a nutshell This study is investigating the effectiveness of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) in early-stage Hodgkin lymphoma (HL). The main outcome that will be measured will be survival without cancer worsening after 18 months. The details There are many different treatments for HL. Each treatment or combination of...
Read MoreDo ACE inhibitors help with anthracycline-induced cardiotoxicity in leukemia and lymphoma?
In a nutshell This study aimed to investigate if enalapril influences anthracycline-induced cardiotoxicity in children with leukemia and lymphoma. This study concluded that enalapril has a role in reducing anthracycline-induced cardiotoxicity in these patients. Some background Anthracyclines are a class of chemotherapy drugs that can be used for...
Read MoreBleomycin and the risk factors for lung problems in Hodgkin lymphoma.
In a nutshell This study investigated the risk factors of developing lung problems after bleomycin (Blenoxane) treatment for Hodgkin lymphoma (HL). It was found that older age may increase the risk of developing lung problems. Some background Bleomycin is an anti-cancer drug, used to treat many types of cancer. Bleomycin is commonly...
Read MoreDoes anti-PD1 therapy change the effectiveness of chemotherapy in unresponsive Hodgkin lymphoma?
In a nutshell This study aimed to investigate the effects of chemotherapy alone or chemotherapy plus anti-PD1 therapy in patients with relapsing/refractory (RR) Hodgkin's Lymphoma. The main finding was that anti-PD1 treatment enhances the effectiveness of chemotherapy in these patients. Some background Stem cell transplant (SCT) and...
Read MoreLate side effects of treatment in long-term Hodgkin’s lymphoma survival”
In a nutshell This is the first study to look at the development of both secondary cancers and cardiovascular disease (CVD) as late side effects of Hodgkin lymphoma (HL) treatment. The study concluded that there was an increased risk of developing both a secondary cancer and CVD in patients treated before 2000. Some background...
Read MoreWhat are the long-term outcomes for HL patients who experience treatment failure after an autologous stem cell transplant?
In a nutshell This study analyzed the survival outcomes of Hodgkin’s lymphoma (HL) patients who experience treatment failure after high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (autoSCT). This study concluded that a second stem cell transplant with or without brentuximab vedotin (Adcetris) may lead to better...
Read MoreCan white blood cell count ratios help predict outcomes for newly diagnosed HL patients receiving PET2-mediated treatment?
In a nutshell This study investigated the impact of white blood cell counts on the outcomes of newly diagnosed Hodgkin’s lymphoma (HL) patients receiving treatment mediated by PET2 (PET scanning after 2 cycles of chemotherapy). This study concluded that ratios of different types of white blood cells combined with PET2 can be a meaningful...
Read MoreOutcomes for Hodgkin lymphoma patients treated with combined modality treatment
In a nutshell This study looked at the long term outcomes for patients with Hodgkin lymphoma who were treated with radiation therapy. The study concluded that patients treated with radiation therapy had better outcomes compared to patients not treated with radiation therapy. Some background Patients with Hodgkin lymphoma (HL) generally have good...
Read More